These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 22532602)

  • 1. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
    Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
    Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
    Ponnurangam S; Standing D; Rangarajan P; Subramaniam D
    Mol Cancer Ther; 2013 May; 12(5):598-609. PubMed ID: 23427297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
    Cui J; Guo Y; Wu H; Xiong J; Peng T
    Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
    Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
    Jung KH; Yan HH; Fang Z; Son MK; Lee H; Hong S; Hong SS
    Int J Oncol; 2014 Jul; 45(1):311-21. PubMed ID: 24819705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
    Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
    Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers.
    Rathos MJ; Joshi K; Khanwalkar H; Manohar SM; Joshi KS
    J Transl Med; 2012 Aug; 10():161. PubMed ID: 22873289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
    Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
    Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
    Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
    Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3,5-bis(2,4-difluorobenzylidene)-4-piperidone, a novel compound that affects pancreatic cancer growth and angiogenesis.
    Subramaniam D; Nicholes ND; Dhar A; Umar S; Awasthi V; Welch DR; Jensen RA; Anant S
    Mol Cancer Ther; 2011 Nov; 10(11):2146-56. PubMed ID: 21890747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts.
    Yau CY; Wheeler JJ; Sutton KL; Hedley DW
    Cancer Res; 2005 Feb; 65(4):1497-504. PubMed ID: 15735038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
    Baker CH; Trevino JG; Summy JM; Zhang F; Caron A; Nesbit M; Gallick GE; Fidler IJ
    Int J Oncol; 2006 Jul; 29(1):125-38. PubMed ID: 16773192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.
    Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Srivastava RK; Shankar S
    Cancer Lett; 2014 Oct; 353(1):32-40. PubMed ID: 25050737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological impact and therapeutic potential of a novel camptothecin derivative (FLQY2) in pancreatic cancer through inactivation of the PDK1/AKT/mTOR pathway.
    Wang W; Xiong H; Li L; Hu X; Zhuang W; Li J; Sun X; Yu Y; Yu Y; Guo Y; Wang Y; Wang R; Wang H; Li Q
    Bioorg Chem; 2024 Jul; 148():107436. PubMed ID: 38735265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative Effects of Matricine in Gemcitabine-Resistant Human Pancreatic Carcinoma Cells Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT Signalling Pathway.
    Fang K; Wang L; Chen L; Liu T; Fang Z
    Med Sci Monit; 2019 Apr; 25():2943-2949. PubMed ID: 31005960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.